Comprehensive Genome Sequencing of Desmoplastic Small Round Cell Tumors
| Registry | NCT01430637 |
|---|---|
| Status | Completed |
| Study type | Observational |
| Enrollment | 20 (Estimated) |
| Sponsor | Children's Oncology Group (Network); collaborators: National Cancer Institute (NCI) |
| Conditions | Sarcoma |
| Interventions | DNA analysis, RNA analysis, gene expression analysis, mutation analysis, nucleic acid sequencing, polymerase chain reaction, laboratory biomarker analysis, pharmacogenomic studies (Genetic, other) |
| Dates | start 2011-09-01, primary completion 2016-05-01, first posted 2011-09-08, last updated 2016-05-18 |
Related Papers Related Patents Related Grants Related Experts
All trials for Sarcoma All trials of DNA analysis All trials of RNA analysis
RATIONALE: Studying samples of blood and tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
PURPOSE: This research study is studying genes in samples from younger patients with desmoplastic small round cell tumor registered on COG-D9902 or COG-ABTR01B1.
OBJECTIVES:
* To perform whole-exome sequencing on desmoplastic small round cell tumor (DSRCT) samples and their available matched normal samples to identify novel mutations, single nucleotide polymorphisms, or copy number changes associated with these tumors.
* To identify regions of interest that may be involved in the pathogenesis (including the region of EWSR1-WT1 translocation) from the whole-exome sequencing and perform detailed resequencing and transcriptone sequencing to further define the molecular aberrations at the RNA level.
OUTLINE: This is a multicenter study.
Archived tumor tissue samples are analyzed for DNA sequencing, effects of RNA on gene expression levels, novel RNA isoforms, splice variants, and translocations.
Sex: All, ages: any to 50 Years
DISEASE CHARACTERISTICS: * Tumor and blood samples from patients registered on COG-D9902 or COG-ABTR01B1 obtained from the Cooperative Human Tissue Network (CHTN) and the Children's Oncology Group (COG) tumor banks * Matched normal samples PATIENT CHARACTERISTICS: * Not specified PRIOR CONCURRENT THERAPY: * Not specified